Mesothelioma Maintenance Chemo | Benefits & Side Effects –

Maintenance chemotherapy is a mesothelioma treatment meant to sustain prior therapy’s effects. It is generally less aggressive than previously administered treatment methods. Its purpose is to slow the advance of mesothelioma cancer. Put another way, it is meant to maintain, for a period of time, the quality of life patients achieve at the end of their initial treatment.
Maintenance chemotherapy tries to balance disease control and quality of life benefits. These goals are different from the goals of first-line treatment.
Initial cancer treatments are usually aggressive attacks meant to shrink and control cancer. These heavy-hitting drugs can be useful in getting the disease under control. But they may result in various side effects. After a while, the benefits of aggressive treatment may no longer outweigh its side effects for the patient. At this point, the goals of treatment can change. Therapy can focus on maintaining the patient’s results while also limiting side effects.
Maintenance chemotherapy usually involves less aggressive drugs than those used during initial treatment. The goal is to both maintain disease control and improve quality of life.
Maintenance chemotherapy is an alternative to supportive care. Many mesothelioma patients receive supportive care after initial treatment. It may include:
Maintenance therapy may be able to provide benefits that supportive care cannot.
Doctors classify maintenance chemotherapy in one of two ways: continuation or switch. The differences between the two types of maintenance chemotherapy are as follows:
Researchers are continuing to investigate both types. Future studies may reveal the benefits of one versus the other to treat different cancers. A doctor can determine which type of maintenance chemotherapy is appropriate for a patient.
The use of maintenance chemotherapy to treat mesothelioma is an ongoing area of study. Researchers have studied possible benefits using specific chemotherapy drugs. Future research may look at using other chemotherapy drugs for mesothelioma maintenance treatment. These may show beneficial results.
One study looked at the use of pemetrexed for pleural mesothelioma maintenance therapy. It concluded that physicians should not use pemetrexed alone for maintenance therapy. The study did not look into possible combination maintenance therapies using pemetrexed. This could be an area for future research.
Another study examined the use of gemcitabine in pleural mesothelioma switch-maintenance therapy. Patients received an initial treatment of platinum and pemetrexed. Among study patients, median progression-free survival was:
These results are promising. Extending progression-free survival may improve quality of life. This is one of the goals of maintenance chemotherapy.
Other chemotherapy drugs may also be useful as maintenance therapies for mesothelioma. Future research can examine different maintenance chemotherapies. It can also examine the use of other types of therapies, such as hormonal therapy and immunotherapy. These may be useful either alone or in combination with chemotherapy drugs.
Maintenance chemotherapy seeks to limit side effects while maintaining quality of life. However, side effects are still possible. They will depend on the kind of drug used for maintenance. Patients can find possible side effects listed on the label of the drug.
Cancer.Net. Understanding Maintenance Therapy. Updated May 2019.
Furst J. Study finds less-aggressive chemotherapy after initial treatment for metastatic colorectal cancer to be more beneficial. Mayo Clinic. December 2019.
Gooijer C, van der Noort V, et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. The Lancet Respiratory Medicine. June 2021;9(6):585-592. doi: 10.1016/S2213-2600(20)30362-3
Incollingo B. What Is the Role of Maintenance Therapy in Cancer Care? OncLive. May 2013.
Kindler H, Ismaila N, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. May 2018;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394
Medicom Medical Publishers. Gemcitabine maintenance after first-line chemo prolongs PFS in malignant mesothelioma. February 2021.
National Cancer Institute. Supportive Care.
Schmid-Bindert G. Maintenance therapy in non-small-cell lung cancer. Translational Lung Cancer Research. June 2012;1(2):105-110. doi: 10.3978/j.issn.2218-6751.2011.10.02
Yu Y, Wang Y, et al. Benefits and risks from maintenance therapy after first-line chemotherapy in patients with metastatic breast cancer. Journal of Clinical Oncology. May 2018;36(15_suppl):1088. doi: 10.1200/JCO.2018.36.15_suppl.1088
By Katy Moncivais, Ph.D.
By Katy Moncivais, Ph.D. is dedicated to providing the latest medical information on mesothelioma, spreading awareness about the dangers of asbestos exposure and providing victims with free resources.
En Español:
¿Qué es el cáncer de mesotelioma?

The editorial team works hard to offer current, factual, expert reviewed information about mesothelioma cancer and the risks of asbestos exposure.
Editorial Guidelines | Disclaimer | Privacy Policy
35 Thorpe Avenue, Suite 101
Wallingford, CT 06492
This site complies with the HONcode standard for trustworthy health information:
verify here.
Copyright © 2022 by All Rights Reserved. The information contained on this site is proprietary and protected. Any unauthorized or illegal use, copying or dissemination will be prosecuted to the fullest extent of the law.
Notice: This website and its content are sponsored by Early, Lucarelli, Sweeney, & Meisenkothen, LLC, a law firm specializing in asbestos injury litigation.
Attorney Advertising. Prior results do not predict a similar outcome. Please read our disclaimer for more information.
Page last modified on May 12, 2022.


Related posts

Leave a Reply

Your email address will not be published.